The Atriva Management

Rainer Lichtenberger, Ph.D. MBA

More than 30 years management in life science Industry, EVP Merckle/ratiopharm group for BD; Since 16 years CEO/COO experience in several SME, raised € 80 Mn venture funds.

Read more

Christian Wallasch, Ph.D.

Seasoned executive management member (COO, CEO) in biopharmaceutical SMEs, such as Axxima and U3, as well as public companies like Intercell/Valneva. Expert in kinase inhibitors, vaccines development, project management and execution.

Read more

Stephan Stenglein, M.D.

Physician trained in Clinical and Molecular Virology with 20 years of accomplishments in pharma, medical device and vaccine development. Previous global management positions with Novartis and AstraZeneca.

Read more

Prof. Oliver Planz, Ph.D.

Universität Tübingen (D), Co-inventor of the technology, expert in antiviral research and translational preclinical R&D up to clinical studies. Advises the WHO on antiviral strategies against influenza.

Read more

Björn Cochlovius, Ph.D., Assoc. Prof.
VP Business Development

20 years leadership positions in SMEs (Head R&D Affitech, CEO OnTarget) and big pharma (Roche, Otsuka, Abbvie). Working experiences in Europe and Asia. Background in R&D, Business Development, M&A, Financing.

Read more

Cees Stouten, M.Sc.
SVP Chemistry Manufacturing Controls,
Site Manager Atriva Therapeutics BV 

Accomplished CMC manager with long-standing and deep experience along the entire development, manufacturing and control value chain,
more than 20 years industry experience

Read more